Tofacitinib Citrate an inhibitor of Janus kinases (JAKs), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
Tofacitinib Citrate is the pharmaceutical salt form of Tofacitinib, a selective Janus kinase (JAK) inhibitor. Produced via citric acid salt formation, its molecular formula is C20H31N8O9P and CAS number is 918604-57-2.
Contraindicated in patients with severe hepatic impairment or active serious infections. Store in tightly sealed containers at controlled room temperature (20°C–25°C) away from moisture to maintain chemical stability.